CA3076202A1 - Cyclic iminopyrimidine derivatives as kinase inhibitors - Google Patents
Cyclic iminopyrimidine derivatives as kinase inhibitors Download PDFInfo
- Publication number
- CA3076202A1 CA3076202A1 CA3076202A CA3076202A CA3076202A1 CA 3076202 A1 CA3076202 A1 CA 3076202A1 CA 3076202 A CA3076202 A CA 3076202A CA 3076202 A CA3076202 A CA 3076202A CA 3076202 A1 CA3076202 A1 CA 3076202A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- quinazolin
- oxy
- mmol
- sulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561142P | 2017-09-20 | 2017-09-20 | |
| US62/561,142 | 2017-09-20 | ||
| PCT/US2018/052047 WO2019060611A1 (en) | 2017-09-20 | 2018-09-20 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3076202A1 true CA3076202A1 (en) | 2019-03-28 |
Family
ID=64457074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076202A Pending CA3076202A1 (en) | 2017-09-20 | 2018-09-20 | Cyclic iminopyrimidine derivatives as kinase inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11254680B2 (https=) |
| EP (1) | EP3684772B1 (https=) |
| JP (1) | JP7394768B2 (https=) |
| KR (1) | KR102796209B1 (https=) |
| CN (1) | CN111247152B (https=) |
| AU (1) | AU2018338098B2 (https=) |
| CA (1) | CA3076202A1 (https=) |
| MX (1) | MX2020003126A (https=) |
| WO (1) | WO2019060611A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PH12022551118A1 (en) * | 2019-12-10 | 2023-09-18 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| CA3179671A1 (en) * | 2020-08-07 | 2022-02-10 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| CN114380697A (zh) * | 2021-11-30 | 2022-04-22 | 上海毕得医药科技股份有限公司 | 一种n-甲基乙基胺盐酸盐的制备工艺 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN117209503B (zh) * | 2023-09-13 | 2025-10-17 | 苏州翔实医药发展有限公司 | 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| TW202545530A (zh) * | 2024-01-17 | 2025-12-01 | 大陸商海思科醫藥集團股份有限公司 | 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用 |
| TW202539670A (zh) * | 2024-02-23 | 2025-10-16 | 大陸商海思科醫藥集團股份有限公司 | Braf抑制劑的製備方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82205C2 (en) * | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| US20100216779A1 (en) | 2007-06-01 | 2010-08-26 | Glaxosmithkline Llc | Imidazopyridine Kinase Inhibitors |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| PL2647637T3 (pl) * | 2010-12-02 | 2016-06-30 | Medpacto Inc | Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf |
| US20130023531A1 (en) | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| CN104703599A (zh) * | 2012-09-14 | 2015-06-10 | 永恒生物科技公司 | 作为蛋白激酶抑制剂的氨基异喹啉衍生物 |
| EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9321762B2 (en) | 2013-12-11 | 2016-04-26 | Development Center For Biotechnology | Quinazoline compounds, method for preparing the same and use thereof |
| CN105272970A (zh) | 2014-07-03 | 2016-01-27 | 中国药科大学 | 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途 |
| MX385110B (es) * | 2014-07-16 | 2025-03-11 | Dev Ct Biotechnology | Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos. |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
-
2018
- 2018-09-20 EP EP18808139.2A patent/EP3684772B1/en active Active
- 2018-09-20 AU AU2018338098A patent/AU2018338098B2/en active Active
- 2018-09-20 KR KR1020207010704A patent/KR102796209B1/ko active Active
- 2018-09-20 WO PCT/US2018/052047 patent/WO2019060611A1/en not_active Ceased
- 2018-09-20 CN CN201880067947.0A patent/CN111247152B/zh active Active
- 2018-09-20 JP JP2020538750A patent/JP7394768B2/ja active Active
- 2018-09-20 MX MX2020003126A patent/MX2020003126A/es unknown
- 2018-09-20 US US16/648,908 patent/US11254680B2/en active Active
- 2018-09-20 CA CA3076202A patent/CA3076202A1/en active Pending
-
2022
- 2022-01-13 US US17/575,292 patent/US11932647B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7394768B2 (ja) | 2023-12-08 |
| US11932647B2 (en) | 2024-03-19 |
| EP3684772B1 (en) | 2023-12-06 |
| RU2020113707A (ru) | 2021-10-20 |
| JP2020534373A (ja) | 2020-11-26 |
| RU2020113707A3 (https=) | 2021-12-23 |
| US20220251089A1 (en) | 2022-08-11 |
| CN111247152A (zh) | 2020-06-05 |
| EP3684772C0 (en) | 2023-12-06 |
| CN111247152B (zh) | 2024-07-16 |
| KR20200055034A (ko) | 2020-05-20 |
| BR112020005455A2 (pt) | 2020-09-24 |
| MX2020003126A (es) | 2020-10-01 |
| AU2018338098A1 (en) | 2020-05-07 |
| AU2018338098B2 (en) | 2024-02-22 |
| EP3684772A1 (en) | 2020-07-29 |
| WO2019060611A1 (en) | 2019-03-28 |
| KR102796209B1 (ko) | 2025-04-16 |
| US20200247813A1 (en) | 2020-08-06 |
| US11254680B2 (en) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932647B2 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| CA3047106A1 (en) | Aminothiazole compounds as c-kit inhibitors | |
| US20210145771A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| CA2916419C (en) | Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
| AU2014312245A1 (en) | Heterocyclic compounds and methods of use | |
| JP2016513685A (ja) | クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 | |
| WO2017083756A1 (en) | Heterocyclic compounds for the treatment of disease | |
| CA3179325A1 (en) | Kinase inhibitors and uses thereof | |
| WO2018211324A1 (en) | Prodrugs for the treatment of disease | |
| TW202434590A (zh) | 稠合雙環化合物 | |
| RU2801302C2 (ru) | Производные циклического иминопиримидина в качестве ингибиторов киназ | |
| TW202229251A (zh) | 乙醯胺基－苯基苯甲醯胺衍生物及其使用方法 | |
| BR112020005455B1 (pt) | Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula | |
| BR112019025158A2 (pt) | Derivados de ácido carboxílico como inibidores das proteínas quinase | |
| CN110724076B (zh) | 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途 | |
| HK40031627A (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| HK40031627B (zh) | 作为激酶抑制剂的环状亚氨基嘧啶衍生物 | |
| WO2025247067A1 (zh) | Kif18A抑制剂 | |
| US9321766B1 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240917 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240917 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250704 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250704 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250812 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260114 |